A recent pilot study published in the Journal of Indian Association of Pediatric Surgeons in October 2026 identified specific genetic alterations in cytochrome P450 17A1 and steroid 5-alpha reductase type 2 in 20% of children with mid-penile hypospadias, compared to none in healthy controls.

Hypospadias is a common congenital male genital anomaly occurring in 1 in 150 to 300 live male births, driven by complex gene-environment interactions affecting fetal androgen signaling during urethral fusion. Although prior international studies implicated polymorphisms in steroid 5-alpha reductase type 2 and cytochrome P450 17A1 in altered androgen availability, genetic data from Indian populations remain scarce; thus, Dr. Bharath Shiva and colleagues from Netaji Subhash Chandra Bose Medical College in Jabalpur, India, evaluated these key gene alleles in mid-penile hypospadias to identify regional molecular markers.

Therefore, the 20-month pilot study in Central India compared 20 children with isolated mid-penile hypospadias against 20 age-matched healthy controls using allele-specific polymerase chain reaction. Excluding other hypospadias subtypes and disorders of sex development, researchers evaluated the detection rates of targeted CYP17A1 and SRD5A2 gene variants between both groups.

Key Clinical Findings of the Study Includes:

  • CYP17-V89L Amplification: Investigators detected cytochrome P450 17A1 V89L allele amplification in 20% (4/20) of mid-penile hypospadias cases compared to 0% (0/20) in healthy control subjects (P < 0.05).
  • SRD5A2 Promoter Polymorphism: Researchers identified steroid 5-alpha reductase type 2 T→C promoter polymorphism amplification in 20% (4/20) of hypospadias patients versus 0% (0/20) in controls (P < 0.05).
  • Dual Gene Involvement: Authors observed concurrent amplification of both gene alleles in 10% (2/20) of patients, suggesting multigene androgen disruption.
  • Subtype Distribution: The study screened 111 total hypospadias patients, revealing distal variants as most prevalent (n=60), followed by proximal (n=31) and mid-penile (n=20) forms.
  • Statistical Significance: Analysis demonstrated significant molecular divergence in targeted androgen pathway markers between mid-penile cases and healthy controls (P < 0.05).

The results suggest that genetic alterations in cytochrome P450 17A1 V89L and steroid 5-alpha reductase type 2 T→C promoter regions are present in 20% of mid-penile hypospadias cases, with 10% exhibiting dual gene involvement. This supports the hypothesis that disrupted enzymatic androgen biosynthesis plays a vital role in abnormal urethral development.

These findings indicate that clinicians might consider incorporating screening for specific androgen biosynthetic gene variants into diagnostic evaluations to better understand underlying etiology and inform patient management.

While constrained by a small sample size, reliance on allele-specific amplification without sequencing, and unmeasured environmental factors, the study highlights the value of expanding future research into larger multicenter cohorts that evaluate comprehensive gene-environment interactions.

Reference

Shiva B, Acharya H, Chakma T, Shanmugam R, Sharma D, Agrawal V. Molecular screening of CYP17A1 and SRD5A2 gene alleles associated with hypospadias: A pilot study from Central India. J Indian Assoc Pediatr Surg 2026;31:1010-4.



Tags:    
Article Source : Journal of Indian Association of Pediatric Surgeons

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .